Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Insulin and Polycystic Ovary Syndrome

This study has been completed.
Information provided by (Responsible Party):
Virginia Commonwealth University Identifier:
First received: May 21, 2008
Last updated: August 19, 2014
Last verified: August 2014
Increased insulin levels leads to increased secretion of D-chiro inositol(DCI) from the kidneys in women with PCOS, but not in normal women. This leads to a reduction in circulating DCI and insulin stimulated release of DCI-IPG.To determine if decreasing circulating insulin directly by inhibition of islet insulin release with diazoxide in obese women with PCOS 1)decreases the renal clearance of DCI and 2) increases the circulating concentration of DCI.

Condition Intervention
Drug: diazoxide

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Determination if Direct Inhibition of Insulin Release With Diazoxide Decreases Renal Clearance of D-Chiroinositol (DCI) and Increases Circulating DCI in Obese Women With Polycystic Ovary Syndrome (PCOS)

Resource links provided by NLM:

Further study details as provided by Virginia Commonwealth University:

Primary Outcome Measures:
  • Renal Clearance of D-chiroinositol (DCI) at 12 Days [ Time Frame: 12 days ]
    Following inhibition of insulin release using diazoxide, measured renal clearance of D-chiro inositol (DCI) via urinary Chiro-inositol dci assay

  • Level of Circulating D-chiro Inositol (DCI) [ Time Frame: 12 days ]
    Measured circulating concentration of plasma DCI following inhibition of insulin release using diazoxide

Enrollment: 21
Study Start Date: November 2005
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PCOS subjects
PCOS subjects given diazoxide
Drug: diazoxide
100mg orally three times per day for 10 days
Active Comparator: Normal subjects
Normal subjects given diazoxide
Drug: diazoxide
100mg orally three times per day for 10 days


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Obese women with PCOS and normal women aged 18-40,
  • PCOS less than 8 periods/year, elevated total or free testosterone, normal thyroid function tests and serum prolactin, exclusion of adrenal hyperplasia
  • Normal regular monthly periods, no clinical evidence of androgen excess,
  • All Acceptable health on interview, medical history, physical exams and lab tests, signed, witnessed informed consent and ability to comply to study requirements

Exclusion Criteria:

  • DM, clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious, neoplastic or malignant disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00683774

United States, Virginia
General Clinical Research Center
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
Principal Investigator: John E. Nestler, MD Virginia Commonwealth University
  More Information

Responsible Party: Virginia Commonwealth University Identifier: NCT00683774     History of Changes
Other Study ID Numbers: VCU IRB 4479
2R01HD035629-09A2 ( US NIH Grant/Contract Award Number )
Study First Received: May 21, 2008
Results First Received: May 30, 2014
Last Updated: August 19, 2014

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Antihypertensive Agents
Vasodilator Agents processed this record on May 24, 2017